Ceribulin 0.88 mg Injection

Injection de Ceribulin 0.88 mg is a potent chemotherapy medication used in the treatment of various types of cancer. Its active ingredient, Ceribulin mesylate, is a synthetic analogue of the marine sponge natural product halichondrin B. Ceribulin works by inhibiting microtubule polymerization, which is essential for cell division. By disrupting the formation of microtubules, it prevents cancer cells from dividing and growing, ultimately leading to their death. This mechanism of action makes it effective against rapidly dividing cancer cells.

Injection de Ceribulin is indicated for the treatment of certain types of advanced or metastatic cancers, particularly those that have not responded to other standard treatments. The typical dosage and administration schedule are determined by the prescribing physician based on the patient’s specific condition, the type and stage of cancer, and their overall health. It is administered intravenously by a healthcare professional.

Common side effects associated with Ceribulin treatment can include myelosuppression (low blood cell counts), fatigue, nausea, vomiting, hair loss, and peripheral neuropathy. Patients should discuss any potential side effects with their doctor. This medication should be stored at room temperature, protected from light and moisture, and kept out of reach of children.